ADC Therapeutics to Participate in SternIR Virtual Corporate Access Event

Rhea-AI Summary

ADC Therapeutics SA (NYSE:ADCT) announced participation in the SternIR Virtual Corporate Access Event from January 11-14, 2021. The pre-recorded presentation will be available for on-demand viewing starting January 11 at 7:00 a.m. ET and can be accessed through their Investors section for 30 days. ADC Therapeutics focuses on developing antibody drug conjugates (ADCs) for oncology, with lead candidates showing promising clinical results in lymphoma treatments.

ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, announced today that management will participate in a pre-recorded presentation and host one-on-one meetings through the SternIR Virtual Corporate Access Event taking place January 11-14, 2021.

The presentation will be available for on-demand viewing beginning Monday, January 11, 2021, at 7:00 a.m. ET. The recording can be accessed via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com, and will be available for approximately 30 days.

About ADC Therapeutics

ADC Therapeutics SA (NYSE:ADCT) is a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors. The Company develops ADCs by applying its decades of experience in this field and using next-generation pyrrolobenzodiazepine (PBD) technology to which ADC Therapeutics has proprietary rights for its

targets. Strategic target selection for PBD-based ADCs and substantial investment in early clinical development have enabled ADC Therapeutics to build a deep clinical and research pipeline of therapies for the treatment of hematological and solid tumor cancers. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to confirmatory Phase 3 clinical trials, in the USA and Europe, and numerous preclinical ADCs in development.

Loncastuximab tesirine (Lonca, formerly ADCT-402), the Company’s lead product candidate, has been evaluated in a 145-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that showed a 48.3% overall response rate (ORR), which exceeded the target primary endpoint. On November 20, 2020, the U.S. Food and Drug Administration accepted the Biologics License Application, granting priority review and setting a Prescription Drug User Fee Act (PDUFA) target action date of May 21, 2021. Camidanlumab tesirine (Cami, formerly ADCT-301), the Company’s second lead product candidate, is being evaluated in a 100-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma (HL) for which preliminary data have demonstrated an 83% ORR, consistent with the Phase 1 clinical trial. The Company is also evaluating Cami in a Phase 1b clinical trial as a novel immuno-oncology approach for the treatment of various advanced solid tumors.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005184/en/

FAQ

What is ADC Therapeutics' participation in the SternIR Virtual Corporate Access Event?

ADC Therapeutics will participate in a pre-recorded presentation and one-on-one meetings at the SternIR Virtual Corporate Access Event from January 11-14, 2021.

When will the ADC Therapeutics presentation be available for viewing?

The presentation will be available for on-demand viewing starting January 11, 2021, at 7:00 a.m. ET.

What are the lead product candidates of ADC Therapeutics?

ADC Therapeutics' lead product candidates include Loncastuximab tesirine (Lonca) and Camidanlumab tesirine (Cami), both showing promising response rates in clinical trials.

What is the target action date for Loncastuximab tesirine's BLA?

The target action date for Loncastuximab tesirine's Biologics License Application is May 21, 2021.

What response rates have ADC Therapeutics' candidates achieved?

Loncastuximab tesirine showed a 48.3% overall response rate in its Phase 2 trial, while Camidanlumab tesirine demonstrated an 83% overall response rate in its pivotal trial.